• Title/Summary/Keyword: Pharmaceutical Industry of Korea

Search Result 260, Processing Time 0.03 seconds

Modern meaning of developing a new medicine in oriental medicine and system of intellectual property (창방의 현대적 의미와 신약, 그리고 지적재산권제도)

  • Choi Hwan-Soo;Kim Yun-Kyung
    • Herbal Formula Science
    • /
    • v.12 no.1
    • /
    • pp.93-104
    • /
    • 2004
  • Recently, more and more natural herbal products are investigated and used popularly. Pharmaceutical companies of Korea are very interested in developing herbal new drugs. And oriental doctors also need popular, modernized form of oriental drugs. The objective of this article is, first, to examine current situations of drug development in Korea, second, to know general concepts of patent and third, to think about new drug development and patent in oriental medicine's point of view. With consideration of oriental medicine's characteristics, concepts of new drug and patent should be improved. Therefore, the oriental pharmaceutical industry and developments of oriental new drugs could be inspired to further efforts.

  • PDF

Ginseng Research in Natural Products Research Institute (NPRI) and the Pharmaceutical Industry Complex in Gaesong (생약연구소의 인삼연구와 약도개성)

  • Park, Ju-young
    • Journal of Ginseng Culture
    • /
    • v.3
    • /
    • pp.54-73
    • /
    • 2021
  • The Natural Products Research Institute (NPRI, 生藥硏究所), an institution affiliated with Keijo Imperial University (京城帝國大學), was the predecessor of the NPRI at Seoul National University and a comprehensive research institute that focused on ginseng research during the Japanese colonial era. It was established under the leadership of Noriyuki Sugihara (杉原德行), a professor of the second lecture in pharmacology at the College of Medicine in Keijo Imperial University. Prof. Sugihara concentrated on studying Korean ginseng and herbal medicine beginning in 1926 when the second lecture of pharmacology was established. In addition to Prof. Sugihara, who majored in medicine and pharmacology, Kaku Tenmin (加來天民), an assistant professor who majored in pharmacy; Tsutomu Ishidoya (石戶谷勉), a lecturer who majored in agriculture and forestry; and about 36 researchers actively worked in the laboratory before the establishment of the NPRI in 1939. Among these personnel, approximately 14 Korean researchers had basic medical knowledge, derived mostly from specialized schools, such as medical, dental, and pharmaceutical institutions. As part of the initiative to explore the medicinal herbs of Joseon, the number of Korean researchers increased beginning in 1930. This increase started with Min Byung-Ki (閔丙祺) and Kim Ha-sik (金夏植). The second lecture of pharmacology presented various research results in areas covering medicinal plants in Joseon as well as pharmacological actions and component analyses of herbal medicines. It also conducted joint research with variousinstitutions. Meanwhile, in Gaesong (開城), the largest ginseng-producing area in Korea, the plan for the Pharmaceutical Industry Complex was established in 1935. This was a large-scale project aimed at generating profits through research on and the mass production of drugs and the reformation of the ginseng industry under collaboration among the Gaesong Ministry, Kwandong (關東) military forces, Keijo Imperial University, and private organizations. In 1936 and 1938, the Gyeonggi Provincial Medicinal Plant Research Institute (京畿道立 藥用植物硏究所) and the Herb Garden of Keijo Imperial University (京城帝國大學 藥草園) and Pharmaceutical Factory were established, respectively. These institutions merged to become Keijo Imperial University's NPRI, which wasthen overseen by Prof. Sugihara as director. Aside from conducting pharmacological research on ginseng, the NPRI devoted efforts to the development and sale of ginseng-based drugs, such as Sunryosam (鮮麗蔘), and the cultivation of ginseng. In 1941, the Jeju Urban Test Center (濟州島試驗場) was established, and an insecticide called Pancy (パンシ) was produced using Jeju-do medicinal herbs. However, even before research results were published in earnest, Japanese researchers, including Prof. Sugihara, hurriedly returned to Japan in 1945 because of the surrender of Japanese forces and the liberation of Korea. The NPRI was handed over to Seoul National University and led by Prof. Oh Jin-Sup (吳鎭燮), a former medical student at Keijo Imperial University. Scholars such as Woo Lin-Keun (禹麟根) and Seok Joo-Myung (石宙明) worked diligently to deal with the Korean pharmaceutical industry.

Development of Technology Portfolio Analysis method for Technology-outsourcing of Pharmaceutical cooperations (제약기업의 기술 아웃소싱을 위한 기술포트폴리오 분석 방법 개발)

  • Hong, Sukchul
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.14 no.11
    • /
    • pp.5809-5818
    • /
    • 2013
  • This study proposes a technology portfolio analysis method for technology outsourcing of pharmaceutical cooperations by applying the concepts of 'Pipeline Soundness' and 'Patent Validity'. This study also applied the developed portfolio analysis method to a 'real world case' of Amgen's acquisition of Onyx Pharmaceuticals to prove the applicability of the method to the real world cases and investigated the validity of the acquisition affair between the two companies. The results of portfolio analysis showed that Amgen's technology portfolio will be improved by acquiring Onyx Pharmaceuticals especially in cancer field which is their main field. So we concluded that Amgen's choice of Onyx pharmaceuticals as a source of technology outsourcing was reasonable. We think that the technology portfolio analysis method developed by this study will be a valuable tool for pharmaceutical cooperations for investigating their current technology status and selecting target companies for technology outsourcing.

Inhibitory effects of Thalictrum rochebrunianum var. grandisepalum on tyrosinase in IBMX-induced B16F10 melanoma cells

  • Jang, Tae-Won;Choi, Ji-Soo;Mun, Jeong-Yun;Im, Jong-Yun;Nam, Su-Hwan;Kim, Do-Wan;Lee, Seung-Hyun;Park, Jae-Ho
    • Proceedings of the Plant Resources Society of Korea Conference
    • /
    • 2019.04a
    • /
    • pp.116-116
    • /
    • 2019
  • Thalictrum rochebrunianum var. grandisepalum (TRG) is a Korean endemic plant, and it is widely used for edible, medicinal, landscape materials. In this study, we examined the protein and mRNA expression levels of MITF, tyrosinase, TRP-1 and TRP-2 by TRG extract (TRGE) in IBMX-treated melanocytes to evaluate the possibility of using TRG as a whitening material. IBMX were reported as melanin synthesis enhancers. It could increase intracellular melanin synthesis by activation of the microphthalmia-associated transcription factor (MITF) signaling pathway. TRGE did not show cytotoxicity at concentrations below $100{\mu}g/ml$ in B16F10 cells. TREG dose-dependently inhibited protein and mRNA levels of MITF, tyrosinase, TRP-1 and TRP-2. Therefore, we suggest that TRGE is an important natural resource for cosmetic raw materials for whitening function.

  • PDF

Current status of natural product industry and its commercial application to health functional foods

  • Park, Jong Dae
    • Proceedings of the Plant Resources Society of Korea Conference
    • /
    • 2018.10a
    • /
    • pp.21-21
    • /
    • 2018
  • Natural product substances have historically served as the most significant also be prepared by source of new leads for pharmaceutical development. They can chemical synthesis(both semisynthesis and total synthesis) and have played a important role in the field of organic chemistry by providing synthetic targets. Rcently, they have also been extended for commercial purpose to refer to medicinal products, health functional foods, dietary supplements and cosmetics from natural sources. A large number of currently prescribed drugs have been either directly derived from or inspired by natural products. However, with the advent of robotics, bioinformatics, high throughput screening(HTS), molecular biology-biotechnology, combinatorial chemistry, in silico(molecular modeling) and other methodologies, the pharmaceutical industry has largely moved away from plant derived natural products as a source for leads and prospective drug candidates. The strategy for natural prduct industry is now changing from drug approaches to health foods by identifying effective natural products as preparations. In Korea, a lot of development of natural product based drugs have been done, but very few on health functional foods. The concept of natural product based health foods is not active components as lead compounds but standardized extracts or preparation mixed with other medicinal plants. The representative material has been recently known to be a standardized ginseng extract "Ginsana G 115" developed by Swiss Pharmaton company. The purpose of this presentation is to underline how natural products research continues to make significant contributions in the domain of discovery and development of new health functional foods. It is proposed to present the development of high value added health food or health functional foods through scientific investigation on efficacy and standardization of new materials form natural products.

  • PDF

Drug Approval-Patent Linkage Systems in the US and Canada (미국과 캐나다의 의약품 허가-특허 연계제도)

  • Park, Sylvia
    • Journal of Pharmaceutical Investigation
    • /
    • v.38 no.3
    • /
    • pp.207-215
    • /
    • 2008
  • Drug approval-patent linkage is the practice of linking drug marketing approval to the patent status of the originator's product and not allowing the grant of marketing approval to any third party prior to the expiration of the patent term unless by consent of the patent owner. Article 18.9.5 of Korea-US Free Trade Agreement requires that Korea introduce the linkage system in drug marketing approval. However, Korea is unfamiliar with the linkage system. In addition, there have been lots of arguments over the impacts of this system on Korean pharmaceutical industry and pharmaceutical market in the future. This report investigated the linkage systems of the US and Canada. The US and Canada have implemented drug approval-patent linkage system since 1984 and 1993, respectively. Both countries have patent lists for drug approvalpatent linkage on which originators are required to list patents on substance, product, and use of their drugs. Generic or follow-on drug applicants must contain a certification regarding each patent listed that relates to the referenced drug. If the patent holder files suit for patent infringement within 45 days of notice of application, drug approval is not allowed for several months - 30 months in the US and 24 months in Canada. Both countries have amended their systems after having experienced unexpected results such as listing improper and additional patents, multiple patent litigations and delayed generic entries. After reviewing the US and Canada's experiences, we suggested three principles needed in implementing the system: protecting patent holder's right; promoting generic drug development and marketing; monitoring the process and the effect of the system.

The impact of the patent through open innovation on the performance of the pharmaceutical and biotechnology firms (글로벌 제약·바이오 기업의 개방형 혁신 특허가 기업 성과에 미치는 영향)

  • Lee, Byoungho;Lee, Sang-Won
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.18 no.9
    • /
    • pp.356-365
    • /
    • 2017
  • Most studies of the effects of corporate patents on managerial performance conducted to date have been based on internally-generated patents. However, global pharmaceutical and biotechnology companies acquire patents not only from internal research and development (R&D), but also through university-industry collaboration and purchase. Focusing on this issue, our study collected patents from various sources, including internal R&D, purchased patents, and university-industry collaboration, to examine the real effects more accurately. Additionally, our study used a finite time lag model to consider the time lag between patent and corporate performance. The results of the quantitative analysis of the relationship between patents and corporate financial performance revealed that patent quantitative levels had less impact on sales than other types. However, quantitative patents levels appeared to have a significant impact on market value. Moreover, quantitative patent levels appeared to moderate impact on corporate profit. Patents acquired by internal R&D had the greatest impact on market value, while purchased patents had the greatest impact on corporate profit and sales. The purchased patents had a significant effect on financial performance in the pharmaceutical and biotechnology companies because of the long time required and expense associated with R&D. Overall, the results of this study provide the basis for global pharmaceutical and biotechnology companies to configure an optimal patent portfolio.

Globalization and Independency of Populist Nations' Welfare Policies: Focusing on the Influences of Multinational Pharmaceutical Companies on the Korean Government's Policy on the Pharmaceutical Industry (세계화와 국민국가의 복지정책 자율성: 다국적 제약자본이 우리나라 제약정책 결정에 미친 영향을 중심으로)

  • Lee, Su-Yun;Kim, Young-Mi
    • Korean Journal of Social Welfare
    • /
    • v.57 no.3
    • /
    • pp.5-30
    • /
    • 2005
  • Globalization has conflicting effects on pharmaceutical policies. A change into a 'populist competitive nation' due to globalization strengthens policies to reduce drug manufacturing costs while the WTO's TRIPS Agreement that is affected by multinational pharmaceutical companies increases drug manufacturing costs by bolstering the patent rights on new drugs. Currently, the independency of populist nations' policies to reduce drug manufacturing cost is being compromised because multinational organizations(such as the European Union) which represents the interests of the multinational pharmaceutical companies put restrictions on the pharmaceutical policies of populist nations for purposes of promoting the industrial goals of the multinational companies. Korea is no exception. Up until the late 1990s, the main feature of the pharmaceutical policies in Korea was keeping the drug price at the cost level based on a growth-driven ideology, and this was Korea's unique policy tools as a developing nation. However, the increase in the power of multinational pharmaceutical companies currently infringes on the independency of Korea's pharmaceutical policies. Expensive imported drugs were originally covered by the national health insurance plan, but starting from 1999 such drugs began to be covered by the plan. After separation of medical and pharmaceutical services, the use of expensive drugs was increased, and the Korean government planned to introduce the reference price policy in order to contain the cost of the national health insurance plan. However, due to pressures from the U.S. government as well as multinational pharmaceutical companies, implementation of the policy has been postponed. In addition, due to a pressure from the U.S. government, a working group was created which would affect the health care policy of the Korean government. Discussions so far on globalization was about whether the change into populist competitive nations due to globalization resulted in the reduction of welfare spending. However, this study shows not only the reduction of health care cost through policies to reduce drug manufacturing costs but increase in welfare spending by raising the strengths of multinational pharmaceutical companies that are for-profit providers of welfare service. While focusing on the contradictory effects of globalization on pharmaceutical policies of a nation, this study looked at how these conflicting effects end up promoting the interests of multinational pharmaceutical companies by examining the Korean case.

  • PDF

Revision of The Korean Pharmceutical Codex, The Third Edition (의약품 등 기준 및 시험방법(제 3개정) 소개)

  • Choi, Myoeng-Sin;Yang, Ji-Sun;Yoo, Tae-Moo;Kim, In-Kyu;Kim, Hye-Soo;Lee, Sun-Hee;Chang, Seung-Yeup;Cho, Jung-Hee;Lee, Su-Jung;Kim, Young-Lim;Kim, Mi-Jeong;Kim, Eun-Jung;Lee, Jong-Pil;Kim, Do-Hoon;Baek, Kyung-Min;Kim, Hee-Sung;Park, Sang-Aeh;Kang, In-Ho;Kim, Eun-Kyung
    • Journal of Pharmaceutical Investigation
    • /
    • v.35 no.3
    • /
    • pp.201-205
    • /
    • 2005
  • The aim of publishing the Korean Pharmaceutical Codex is to update and set specification of essential drugs for humane health. In accordance with speedy development of new drugs and improvement of science and technology, the need of revision of drug specification through the ICH guidelines and discussions between regulatory agency and pharmaceutical industry for the quality assurance of safer and efficient drugs is getting higher. The first edition of Korean Pharmaceutical Codex was published in 1983. Now, the third revision of the Codex is prepared because of the revision of domestic and foreign Pharmacopeias, changes of drug control environment, improvement of science and technology and so on. The aim of 3th edition is to improve the quality of essential drugs through the setting of the required specifications and discussions between the regulatory agency and pharmaceutical industry.

Long-term Outlook and Implications of the Marine Biotechnology Market in Korea and Abroad (국내외 해양생명공학 산업시장의 장기예측 및 함의)

  • Jang, Duckhee;Kang, Gilmo;Chae, Gi-Young;Kim, Soo-Ji;Jo, Min-Ju;Cha, Jeong-Mi;Ham, Hyun-Kyung
    • Ocean and Polar Research
    • /
    • v.35 no.2
    • /
    • pp.93-105
    • /
    • 2013
  • The marine biotechnology industry is very significant as compared to other industries as one of the driving forces for economic growth in the next generation in Korea. However, the marine biotechnology market has been considered as a component of the biotechnology industry market which made difficult for creating separate research areas in relation to the scope of the relevant industry market as well as making it difficult to establish its own R&D policy strategies. Accordingly, this study was executed to estimate the future long-term market value of the marine biotechnology within the limit of industrial field and to verify the importance of national R&D investment in marine biotechnology on the basis of estimations within the industrial perspective. To this end, we classified the marine biotechnology industry into the four sub-sectors and estimated the domestic and global industrial market in 2010 and 2024. According to the results, the domestic and global market of the marine biotechnology industry will see a remarkable growth by 2024. In particular, the bio-energy, pharmaceutical and functional foods industry markets will achieve astonishing advances. On the basis of the analysis results, Korea has to establish more progressive and aggressive R&D investment strategies to strengthen national competitiveness through the marine biotechnology industry.